A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This study will test an experimental drug (enfortumab vedotin) alone and with different
combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor (CPI)
that is used to treat patients with cancer of the urinary system (urothelial cancer). This
type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra. Some parts of
the study will look at locally advanced or metastatic urothelial cancer (la/mUC), which means
the cancer has spread to nearby tissues or to other areas of the body. Other parts of the
study will look at muscle-invasive bladder cancer (MIBC), which is cancer at an earlier stage
that has spread into the muscle wall of the bladder. This study will look at the side effects
of enfortumab vedotin alone and with other anticancer therapies. A side effect is a response
to a drug that is not part of the treatment effect. This study will also test if the cancer
shrinks with the different treatment combinations.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Astellas Pharma Global Development, Inc.
Collaborators:
Merck Sharp & Dohme Corp. Seagen Inc. Seattle Genetics, Inc.